Showing 6271-6280 of 6635 results for "".
- Potential New Diagnostic Tools and Therapies for Melanoma in the Foreseeable Futurehttps://practicaldermatology.com/news/20140512-potential_new_diagnostic_tools_and_therapies_for_melanoma_in_the_foreseeable_future/2459241/Oregon State University researchers have identified a biochemical process that may cause normal and healthy skin cells to transform into cancerous melanoma cells. These findings could help predict melanoma exposure and could also lead to future treatments. Melanoma, the deadliest form of
- TetraLogic Pharmaceuticals Presents SHAPE at Annual Society of Investigative Dermatology Meetinghttps://practicaldermatology.com/news/20140506-tetralogic_pharmaceuticals_presents_shape_at_annual_society_of_investigative_dermatology_meeting/2459246/TetraLogic Pharmaceuticals Corporation presented results from the Phase I randomized, placebo-controlled clinical study of SHAPE (formerly SHP-141) in Stage IA -IIA Cutaneous T Cell Lymphoma (CTCL) at the annual Society of Investigative Dermatology Meeting, which was held in Albuquerque, New Mexi
- derma e Scar Gel Proves Effective in Clinical Trialhttps://practicaldermatology.com/news/20140502-derma_e_scar_gel_proves_effective_in_clinical_trial/2459247/The results of an independent clinical trial on derma e Scar gel formula proved the formula effective for participants who used the product for an eight-week period. Derma e Scar gel is a naturally therapeutic treatment that is designed to smooth, soften, and decrease the look of
- Syneron Candela Achieves Approval to Market Its ALEX II System in Japanhttps://practicaldermatology.com/news/20140429-syneron_candela_achieves_approval_to_market_its_alex_ii_system_in_japan/2459250/Syneron Medical Ltd.'s subsidiary in Japan, Candela KK, received registration approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its ALEX II system in Japan for the treatment of benign dermal lesions.&nbs
- The American Society for Dermatologic Surgery Accreditation Program Applications Due June 15https://practicaldermatology.com/news/20140428-the_american_society_for_dermatologic_surgery_accreditation_program_applications_due_june_15/2459252/Dermatology programs and practices trying to start a fellowship program have until June 15 to apply for accreditation cosmetic program. The program focuses on six topics: patient care, medical knowledge, practice-based learning, interpersonal skills, professionalism, and system-based practice.
- Novan Therapeutics to Present Data at 2014 Society for Investigative Dermatology Annual Meetinghttps://practicaldermatology.com/news/20140425-novan_therapeutics_to_present_data_at_2014_society_for_investigative_dermatology_annual_meeting/2459255/Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, will present data from the Phase 2 clinical trial in acne vulgaris with its lead product candidate, SB204, at the 2014 Annual Meeting of the Society for Investigative Dermatol
- Nuvo Research Announces Collaboration to Develop Topical Dermatology Productshttps://practicaldermatology.com/news/20140423-nuvo_research_announces_collaboration_to_develop_topical_dermatology_products/2459258/Nuvo Research Inc. is collaborating with Ferndale Laboratories, Inc. and a leading Contract Research Organization (CRO) with significant dermatology experience to develop two topical dermatology products based on Nuvo's patented Multiplexe
- Innocutis Introduces Dexter the Dystrophic Nail to Educate Patientshttps://practicaldermatology.com/news/20140417-innocutis_introduces_dexter_the_dystrophic_nail_to_educate_patients/2459265/Innocutis launched an animated social media campaign to educate on the prevalence of nail dystrophy and Nuvail as a viable treatment option. The antagonist of healthy nails in what the company calls a “fun, light-hearted, social media campaign” is
- Residents Provided with Online Education by ASDShttps://practicaldermatology.com/news/20140416-residents_provided_with_online_education_by_asds/2459270/Kyle M. Coleman, MD, has developed a dermatologic surgery educational series as part of the ASDS Future Leaders Network. The "Better Surgical Education" video series, focusing on dermatologic surgery topics and procedures, will provide additional education opportunities for residency programs.
- TetraLogic Acquires Shape Pharmaceuticals, Inc.https://practicaldermatology.com/news/20140407-tetralogic_acquires_shape_pharmaceuticals_inc/2459275/TetraLogic Pharmaceuticals Corporation has entered an agreement to acquire Shape Pharmaceuticals, a biotechnology company. Shape Pharmaceuticals is developing SHAPE, which is a tissue-targeted HDAC inhibitor in a topical gel formulation to treat stage IA-IIA Cutaneous T-Cell Lymphoma.